Reported 8 months ago
On June 19, 2024, at 4:10 pm, ITRI and Jabil announced an expanded cross-border cooperation platform for biomedical innovation. Jabil Chairman Chen Chih-Hong stated that the group has investments in hospitals, pharmacies, and medical materials, with expected medical business revenue surpassing 30 billion TWD this year. Through collaboration with the biomedicine sector, Jabil plans to accelerate product mass production and sales, aiming to develop Taiwan's medical industry into a safeguard for the country. Jabil has been deeply involved in the medical field for nearly 20 years, operating institutions like Chung Shan Medical University Hospital, and expanding into medical consumables, dental, audiology, hemodialysis, medical aesthetics, medical management, and pharmacy channels. With a revenue of about 25.2 billion TWD from medical businesses last year and an expected breakthrough of 30 billion TWD this year, Jabil's efforts in the medical field will continue to grow. Collaborating with ITRI, a significant driver of industrial development in Taiwan, aligns with Jabil's strategic plans and strengths, with a focus on various medical necessities and services for future expansion and growth.
Source: YAHOO